Lyfebulb Announces the Lyfebulb Innovation Award with Novo Nordisk A/S

The Award Recognizes Patient Entrepreneurs’ Innovative Efforts and Ideas for Management of Diabetes Using Consumer, Medical Devices or Healthcare Information Technologies

NEW YORK, NY / ACCESSWIRE / August 16, 2016 / Lyfebulb, a patient-centric company that empowers patient entrepreneurs to deliver innovative products and solutions to patients living with chronic disease, announces the Lyfebulb Innovation Award with Novo Nordisk A/S.

The Lyfebulb Innovation Award serves to spotlight outstanding patient entrepreneurs’ innovative efforts and ideas to manage diabetes better using consumer or medical devices, or healthcare information technology. Ten finalists and the winner of the Award will be selected by a panel comprising patient key opinion leaders, Lyfebulb founders, and senior device researchers from Novo Nordisk. The ten finalists will be invited to participate at an Innovation Summit on 6-7 December 2016, hosted by Novo Nordisk in Copenhagen, Denmark. This summit and the award will give the finalists, and the winner in particular, visibility and recognition, as well as professional discussion and inspiration for developing ideas further.

“We are excited to collaborate on the Innovation Summit and the Award with Novo Nordisk,” says Dr. Karin Hehenberger, CEO and Founder of Lyfebulb. “Providing exposure and recognition for patient entrepreneurs is important when they take the next steps to advance solutions for patients. For the wider community of people living with diabetes, this will be inspiring and motivational, exactly in line with the Lyfebulb Mission.”

Senior Vice President for Novo Nordisk Device R&D Kenneth Strømdahl adds: “Patient entrepreneurs have a unique position and passion for developing innovative solutions to improving the life of people living with diabetes. We are happy to embrace their growing role in the landscape of healthcare, and I look forward to being inspired by their passion and insights at the Innovation Summit.”

All candidates are invited to submit applications on the Lyfebulb Innovation Award website at apply.lyfebulb.com. Submission may be made between 15 August 2016 and 30 September 2016.

About Lyfebulb

Lyfebulb is a business focused on bringing innovative products and solutions focused on chronic disease to market. Lyfebulb serves as a bridge between patients and industry, and its mission is to improve the quality of life of those living with chronic disease NOW.

See www.lyfebulb.com, Facebook, Twitter, Instagram, Karin Hehenberger LinkedIn, and Lyfebulb LinkedIn.

Press Contact for Lyfebulb:

Karin Hehenberger, MD, PhD
CEO Lyfebulb
Phone: 917-575-0210
Email: karin@lyfebulb.com

Or

Vivian Cervantes
Managing Director, PCG Advisory Group
Phone: 212-554-5482
Email: vivian@pcgadvisory.com

Consumer Press Contact for Lyfebulb:

People’s Revolution – Kelly Cutrone & Simone Francese
62 Grand Street, 3rd Floor New York, New York 10013
Phone: 212-274-0400
Email: simone.francese@peoplesrevolution.com

About Novo Nordisk

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 42,300 people in 75 countries and markets its products in more than 180 countries. For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube

SOURCE: Lyfebulb

ReleaseID: 443846